Skip to main content

Market Overview

UPDATE: Canaccord Genuity Downgrades Optimer Pharmaceuticals Following Merger Proposal


In a report published Wednesday, Canaccord Genuity analyst Ritu Baral downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold, and lowered the price target from $22.00 to $13.00.

In the report, Canaccord Genuity noted, “Lowering to HOLD, $13 target on the expectation of proposed merger to close and a payout event to be triggered in 2015 tied to strong Dificid performance. We think the superior clinical profile, strong pharmacoeconomics, and integrated SG&A synergy for Dificid will drive solid uptake, despite premium pricing. Our $13 target is derived from a pNPV sum-of-the-parts analysis based on varying payout scenarios.”

Optimer Pharmaceuticals closed on Tuesday at $13.29.

Latest Ratings for OPTR

Jul 2013JefferiesDowngradesBuyHold
Jul 2013Canaccord GenuityDowngradesBuyHold
May 2013BairdDowngradesOutperformNeutral

View More Analyst Ratings for OPTR
View the Latest Analyst Ratings


Related Articles (OPTR)

View Comments and Join the Discussion!

Posted-In: Canaccord Genuity Ritu BaralAnalyst Color Downgrades Analyst Ratings

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at